1. IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy;
2. Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy;
3. Department of Medicine, University of Tennessee, Knoxville, TN;
4. Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy;
5. Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;
6. Department of Hematology, Concord Hospital, University of Sydney, Sydney, NSW, Australia;
7. Department of Medicine, Jewish General Hospital Montreal, Montreal, QC, Canada;
8. Casa de Saúde Santa Marcelina, São Paulo, Brazil;
9. Department of Medicine, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil;
10. Department of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil;
11. Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia;
12. Department of Medical Oncology, Pretoria East Hospital, Pretoria, South Africa;
13. Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey;
14. Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan;
15. Merck & Co., Inc., Kenilworth, NJ; and
16. Princess Margaret Cancer Centre, Toronto, ON, Canada